About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

New Test Helps Diagnose Intellectual Disability in Children

Scan tracks entire genome from a blood sample
FRIDAY, Jan. 17, 2014 (HealthDay News) -- A new test to help diagnose developmental delays and intellectual disability in children based on genetic abnormalities has been approved by the U.S. Food and Drug Administration.
The Affymetrix CytoScan DX Assay scans the entire genetic code from a blood sample and detects chromosomal variations that can lead to developmental and learning problems in children, the agency said Friday in a news release.
Intellectual disability affects as many as 3 percent of children in the United States, the agency said.
Analysis of 960 blood specimens found the new test was better at detecting chromosomal abnormalities that could lead to intellectual disability than other standard tests, the FDA said.
The new test is produced by Affymetrix Inc., based in Santa Clara, Calif.
More information
Medline Plus has more about intellectual disability (http://www.nlm.nih.gov/medlineplus/ency/article/001523.htm ).
Health Headlines
Scientists Discover New Way to Make Human PlateletsView in a lightbox
No Change in Heart Attack Rates for Younger U.S. AdultsView in a lightbox
Animal Experiments Shed Light on HIV's Ability to HideView in a lightbox
Asthma Drug May Help Those With Chronic HivesView in a lightbox
Common Genes Implicated in Autism StudyView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices